Mutations in the E3 ubiquitin ligase parkin (PARK2, also known as PRKN) and the protein kinase PINK1 (also known as PARK6) are linked to autosomal-recessive juvenile parkinsonism (AR-JP) 1, 2 ; at the cellular level, these mutations cause defects in mitophagy, the process that organizes the destruction of damaged mitochondria 3, 4 . Parkin is autoinhibited, and requires activation by PINK1, which phosphorylates Ser65 in ubiquitin and in the parkin ubiquitin-like (Ubl) domain. Parkin binds phospho-ubiquitin, which enables efficient parkin phosphorylation; however, the enzyme remains autoinhibited with an inaccessible active site 5, 6 . It is unclear how phosphorylation of parkin activates the molecule. Here we follow the activation of full-length human parkin by hydrogendeuterium exchange mass spectrometry, and reveal large-scale domain rearrangement in the activation process, during which the phospho-Ubl rebinds to the parkin core and releases the catalytic RING2 domain. A 1.8 Å crystal structure of phosphorylated human parkin reveals the binding site of the phospho-Ubl on the unique parkin domain (UPD), involving a phosphate-binding pocket lined by AR-JP mutations. Notably, a conserved linker region between Ubl and the UPD acts as an activating element (ACT) that contributes to RING2 release by mimicking RING2 interactions on the UPD, explaining further AR-JP mutations. Our data show how autoinhibition in parkin is resolved, and suggest a mechanism for how parkin ubiquitinates its substrates via an untethered RING2 domain. These findings open new avenues for the design of parkin activators for clinical use.
. It has further been suggested that targeted activation of either PINK1 or parkin could increase mitochondrial turnover and impede the progression of Parkinson's disease. A detailed under standing of the underlying molecular mechanisms of these processes is therefore essential.
Parkin requires an elaborate activation mechanism. The first crystal structures of parkin [7] [8] [9] revealed several distinct mechanisms of auto inhibition (Fig. 1a, Extended Data Fig. 1a ). Most strikingly, the active site Cys on the catalytic RING2 domain, which receives ubiquitin from the E2 enzyme, is obstructed by an interface with the UPD (also known as RING0) (Extended Data Fig. 1a) . The RING2-UPD interface is highly hydrophobic [7] [8] [9] (Extended Data Fig. 1b) , and it is not clear how this intramolecular interaction can be opened.
Activation of parkin is mediated by the mitochondrial outer membrane (MOM) Ser/Thr protein kinase PINK1, which phospho rylates Ser65 in ubiquitin (generating phosphoubiquitin) [10] [11] [12] [13] [14] and in the parkin Ubl domain [15] [16] [17] . A current model for PINK1mediated activation of parkin suggests that PINK1 phosphorylates ubiquitin attached to MOM proteins, and autoinhibited, cytosolic parkin is recruited with nanomolar affinity to sites of PINK1 activity 3, 5, 13, [18] [19] [20] [21] . Binding of phosphoubiquitin induces conformational changes in par kin that lead to the release of the Ubl domain from the parkin core, and enable PINK1 to phosphorylate the parkin Ubl domain 3, [5] [6] [7] 13, [18] [19] [20] [21] [22] ( Fig. 1a, Extended Data Fig. 1c) . Notably, in structures of parkin bound to phosphoubiquitin 5, 6 , parkin is still autoinhibited; the E2 binding site remains blocked by the repressor (REP) element, and RING2 and its catalytic Cys remain obstructed by the UPD (Fig. 1a, Extended  Data Fig. 1c) .
Indeed, full activation of parkin requires phosphorylation of its Ubl. A parkin S65A mutant is not retained at mitochondria, is unable to trigger mitochondrial ubiquitination and mitophagy, and thus is physio logically inactive 13, 15, 17, 21, 23 . Biochemically, parkin phosphorylation enhances activity to a greater extent than binding of phospho ubiquitin 13, 21, 24 , and parkin phosphorylation, but not phospho ubiquitin binding, enables ubiquitin activitybased probes (UbABPs) to access the active site Cys 5, 13, 25 . How Ubl phosphorylation is able to activate parkin, and in particular, how it can disrupt the RING2-UPD interface, has remained unknown, and this has led to various models of parkin activation 3, 5, 6, 8, 9, 26 . We reconstituted activation of fulllength human parkin by PINK1, and followed domain rearrangements by hydrogen-deuterium exchange mass spectrometry (HDXMS) 27 ( Fig. 1b -e, Extended Data Figs. 2, 3) . HDXMS reports on the relative rate of exchange of backbone amide hydrogens with deuterium, based on the strength of hydrogen bonding and solvent accessibility in the folded protein, and distinguishes peptides in a protein's core (which show no or little exchange with solvent over time) from those at an exposed surface (which show high or increasing exchange with solvent over time). The power of the method lies in its ability to compare identical peptides between different states along an activation cascade, revealing pep tides that become exposed and thus interfaces that are opened (red in Fig. 1b-e) , and regions in the protein that become protected and form new interfaces (blue in Fig. 1b-e ). For parkin, this allowed us to confirm previously reported conformational changes upon phospho ubiquitin binding 5, 6 , whereby the parkin Ubl is released and becomes exposed to solvent (numbers 1 and 2 in Fig. 1b) , the phosphoubiquitin binding site becomes protected (3) , and RING2, REP (4) and UPD are essentially unperturbed (Fig. 1b, Extended Data Fig. 3a) .
Phosphorylation of parkin initiates release of REP and RING2 (4, 5) , especially at later time points, but the phosphorylated Ubl also remains flexible and in exchange with solvent (1) (Fig. 1c, Extended Data  Fig. 3b ). The behaviour of phosphoUbl changes markedly when a covalent, nondischargeable E2-ubiquitin conjugate is added to the sample-now, the Cterminal RING2 peptide at the UPD interface is exposed to solvent (5) , and the phosphorylated Ubl becomes protected (1) , indicating the formation of a new interface (Fig. 1d , Extended Data Figs. 2, 3c). Finally, charging of the catalytic Cys of RING2 by ubiquitin was assessed using phosphorylated parkin covalently modified with the UbABP ubiquitinvinylsulfone (UbVS) 5, 13 (see Methods, Extended Data Fig. 2a-c) . 'Charged' phosphoparkin reiterates the conforma tional changes observed in the phosphoparkin E2-Ubbound sample (Fig. 1e, Extended Data Fig. 3d) , showing that the ubiquitinmodified RING2 had been fully released from the parkin core (5) . Overall, the HDXMS experiments indicated that there were considerable re arrangements of Ubl and RING2, with loss of old and formation of new intramolecular interfaces on the parkin core ( Unexpectedly, a section of the linker between Ubl and UPD was protected during rebinding of the phosphoUbl (6) (Fig. 1d , e, Extended Data Figs. 2, 3 ). This region of parkin, spanning amino acids 75-145,
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has remained unstudied as it is disordered in fulllength parkin 7 and was removed in subsequent structures of human and rat parkin 6, 18, 19 . The Ubl-UPD linker contains two connected, short sections of highly conserved residues that are flanked by a variable number of unconserved residues (Extended Data Fig. 4) . A minimal linker is pres ent in Thamnophis sirtalis (Ts) parkin (garter snake parkin, sequence identity to human parkin 73%, Extended Data Fig. 4) , and Tsparkin was used for comparative studies. HDXMS revealed highly similar changes upon ubiquitin charging in phosphorylated Tsparkin when compared to human parkin (Extended Data Fig. 5a , with Fig. 1e ). Moreover, limited proteolysis of fulllength Tsparkin revealed that auto inhibited, unphosphorylated Tsparkin was cleaved first in the Ubl-UPD linker, whereas phosphorylated Tsparkin was cleaved first in the IBR-RING2 linker, and was not efficiently cleaved in the Ubl-UPD linker (Extended Data Fig. 5b ). After cleavage of phosphoTsparkin, RING2 was no longer stably associated with the parkin core (Extended Data  Fig. 5c ). Together, these data again strongly suggest that the unstudied Ubl-UPD linker becomes ordered in activated parkin, whereas REP and RING2 are dislodged, and RING2 becomes mobile.
We realized that crystallographic analysis of active parkin was likely to be impeded by a mobile RING2 domain, and this inspired new construct design. Parkin is insoluble when expressed without the RING2 domain (data not shown), probably owing to the exposed, hydrophobic UPD (Extended Data Fig. 1b) . Hence, we engineered a tobacco etch virus (TEV) cleavage site into the IBR-RING2 linker (Fig. 2a, see Methods) . This enabled us to remove the RING2 domain upon phosphoubiquitin binding and Ubl phosphorylation (Extended Data Fig. 5d ). Notably, UbVScharged Tsparkin and Tsparkin lacking RING2 (Tsparkin∆RING2) displayed identical difference HDXMS profiles, indicating that removal of the mobile RING2 had no effect on the remaining molecule (Extended Data Fig. 5e ). For human parkin, the resulting covalent phosphoparkin∆RING2-phosphoubiquitin (hereafter phosphoparkin-phosphoubiquitin) complex was crystal lized, and resulted in a 1.8 Å structure (Fig. 2b , Extended Data Table 1 , Extended Data Fig. 6 ).
The structure of phosphoparkin-phosphoubiquitin (Fig. 2b ) revealed a nearidentical organization of the parkin core (UPD-RING1-IBR) bound to phosphoubiquitin, as compared to previous structures (r.m.s.d. 0.73 Å with human parkin-phosphoubiquitin, PDB 5N2W 6 ) (Extended Data Fig. 7a [7] [8] [9] . Middle, binding of phosphoubiquitin (pUb) to parkin releases the Ubl domain, but most mechanisms of autoinhibition remain 5, 6 . Right, after Ubl phosphorylation, parkin is fully active (green circles), but a structure of active parkin has not been reported. Also see Extended Data Fig. 1 . b-e, HDXMS difference maps with the shortest peptides covering any given region, coloured from blue (more protected from exchange compared to previous state) to red (more accessible to solvent exchange). Peptides for grey regions could not be analysed (see Extended Data Fig. 3 ). The five columns per sample indicate different time lengths for hydrogen-deuterium exchange (0.3 s, 3 s, 30 s, 300 s and 3,000 s). All experiments were performed with human fulllength parkin, as technical triplicates. See Extended Data Figs. 2, 3 for raw data and structural mapping, respectively. b, Difference between parkin and parkin bound to phosphoubiquitin. c, Difference between parkin-phospho ubiquitin and phosphoparkin-phosphoubiquitin. d, Difference between phosphoparkin-phosphoubiquitin, and phosphoparkin-phospho ubiquitin bound to a nondischargeable UBE2L3-ubiquitin (Ub) complex (see Methods). e, Difference between phosphoparkin-phospho ubiquitin and phosphoparkin-phosphoubiquitin charged with UbVS (see Methods). Fig. 1d, Extended Data Fig. 3c) .
Notably, the phosphorylated Ubl domain was bound to the UPD, and had moved by more than 50 Å from its position in autoinhibited parkin (Figs. 2b, 3a, Extended Data Fig. 7a ). The interface between phosphoUbl and UPD is mediated by a common interaction site of ubiquitinfold modifiers, the hydrophobic Ile44 patch of the Ubl, and engulfs the elongated UPD domain covering a surface of more than 800 Å 2 ; this interface can be recapitulated in HDXMS data (Fig. 1d, e , Extended Data Fig. 7c) . Furthermore, the interaction places phospho rylated Ser65 into a positively charged pocket on the UPD (Fig. 3a) . The phosphoacceptor pocket is lined by Lys161, Arg163 and Lys211, which contact the phosphate group and form four hydrogen bonds. We had previously noted this putative phosphateacceptor binding site 8 , the importance of which is highlighted by two mutations found in patients with ARJP (K211N and K161N) 1,2 that also abrogate the function of parkin in mitophagy 13, 29 . Mechanistically, phosphorylated parkin with a K211N mutation blocking the phosphoacceptor pocket was no longer modified by UbVS 5 (Fig. 3b) . HDXMS confirmed that phosphoparkin-phosphoubiquitin(K211N) showed little sign of RING2 release and had the strongest relative solvent protection in the C terminus, where RING2 binds the UPD (Fig. 3c, Extended Data  Fig. 7d ). This indicated that the catalytic Cys of the RING2 domain remained inaccessible if phosphoUbl was unable to interact with its UPD binding site, and explained how ARJPcausing K211N or K161N mutations produce parkin variants that cannot be activated by Ser65 phosphorylation.
The position of the Ubl on the UPD overlaps only marginally with the position of RING2 in autoinhibited states of parkin, and while binding of both would lead to steric clashes (Fig. 3d , Extended Data Fig. 7a ), the hydrophobic RING2 binding site (Extended Data Fig. 1b ) would remain unusually exposed upon opening of the RING2-UPD interface. In our structure, clear electron density for a stretch of resi dues was apparent at the RING2binding site of the UPD (Extended Data Fig. 6c ), and we could unambiguously assign this density to the sequence corresponding to the first conserved region of the Ubl-UPD linker (Fig. 4, Extended Data Figs. 4, 6 ). In particular, residues Leu102, Val105 and Leu107 occupy pockets previously bound by RING2 res idues Met458, Trp462 and Phe463 (Fig. 4a, b) . Hence the Ubl-UPD linker shields the hydrophobic patch on the UPD that was opened by release of RING2. Indeed, similar to the K211N mutation, phospho parkin with deletion of the first set of conserved linker residues (∆101-109) was unable to be charged by UbVS (Fig. 4c) .
The linker provides additional contact points for the phosphoUbl interface. Arg104 is located between two key hydrophobic residues, and contacts with its side chain the Ser65 loop in phosphoUbl. Notably, parkin(R104W) is a mutation found in patients with ARJP 2, 30 , and we would predict that this mutation would disrupt or misalign the observed hydrophobic interactions. A phosphoparkin(R104A) mutant was charged less efficiently by UbVS (Fig. 4d) , showed slower E2-Ub discharge activity (Extended Data Fig. 8a, b) and reduced in vitro poly ubiquitination activity (Fig. 4e) , whereas its thermal stability remained unperturbed (Extended Data Fig. 8c) .
Together, structural, biochemical and patient data confirm the cru cial importance of the first conserved stretch of the Ubl-UPD linker for parkin activity, and define a new activating element, which we term ACT, in this understudied regulatory region of parkin, which also con tains several phosphorylation sites (see further discussion in Extended Data Fig. 8d ).
Our work resolves the activation mechanism of parkin, finally visu alizing largescale domain rearrangements and showing that the parkin Ubl switches between an inhibitory position in the unphosphorylated molecule to an activating position in phosphorylated parkin. Our data are consistent with a model in which the phosphorylated Ubl and the ACT element in the Ubl-UPD linker dislodge RING2 from its auto inhibited position, enabling it to be charged by E2-Ub, and ubiquiti nate substrates in its vicinity independently of the parkin core (Fig. 4f) . Notably, our model does not require parkin dimerization 6, 26 . Our structure of an activated parkin core will inform drug discovery efforts that have set out to identify parkin activators. With the realiza tion that the RING2-UPD interface opens and exposes a hydropho bic pocket, small molecules could be directed towards this interface. Such molecules may become particularly useful to restart mitophagy in patients with ARJP who carry parkin variants that are not activated by PINK1mediated Ubl phosphorylation. 
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The authors declare no competing interests. ). Sitedirected mutagenesis was carried out using the QuikChange protocol with Phusion polymerase. A TEV cleavage site was introduced into the parkin constructs using the NEB Q5 SiteDirected Mutagenesis Kit (NEB). In Tsparkin, residues 368-374 (KSPGATA) were replaced by the ENLYFQS TEV cleavage sequence, while in Hsparkin residues 382-378 (EASGTTT) were replaced by the TEV cleavage sequence to yield cleavable constructs. Protein purification. For parkin expression, Escherichia coli Rosetta2 pLacI cells (Novagen) were grown in 2×TY medium at 37 °C. At OD 600 = 0.6 the temperature was reduced to 18 °C; expression was induced at OD 600 = 0.8-1.0 with 30 µM IPTG and the medium supplemented with 200 µM ZnCl 2 . Cells were harvested after overnight growth at 18 °C and frozen at −20 °C.
Additional information
For parkin purification, cells were resuspended in lysis buffer (300 mM NaCl, 10% (w/v) glycerol, 25 mM Tris (pH 8.5), 14.3 mM βmercaptoethanol) supplemented with 2 mg/ml lysozyme, 0.2 mg/ml DNaseI and 80 µg/ml PMSF. The suspension was homogenized using an EmulsiFlexC3 (Avestin) for two passes at ~15,000 p.s.i. and cleared by centrifugation at 46,000g for 35 min at 4 °C. The clarified lysate was applied to Amintra glutathione resin (Expedeon), resin washed with high salt buffer (25 mM Tris (pH 8.5), 500 mM NaCl, 10 mM DTT) and GSTfusion parkin cleaved from the resin overnight at 4 °C with GST3C protease.
Samples were eluted and resin washed with nosalt buffer (25 mM Tris (pH 8.5), 10 mM DTT). All following purification steps were carried out on an Äkta Pure system (GE Healthcare). Pooled fractions were subjected to anionexchange chromatography on a 6ml Resource Q column (GE Healthcare) with a 0-25% linear gradient from buffer A (25 mM Tris (pH 8.5), 10 mM DTT, 50 mM NaCl) to buffer B (25 mM Tris (pH 8.5), 10 mM DTT, 1,000 mM NaCl) over 15 column volumes. For phosphorylated parkin, the resulting sample was phosphorylated using a 1:100 molar ratio of GST-PhPINK1 in phosphorylation buffer (10 mM ATP, 10 mM MgCl 2 , 200 mM NaCl, 50 mM Tris (pH 8.5), 10 mM DTT). PINK1 was subsequently removed by incubation with Amintra glutathione resin (Expedeon) and phosphorylated parkin purified using anion exchange chromatography as above. Finally, samples were subjected to sizeexclusion chromatography (HiLoad 16/600 Superdex 75 pg, GE Healthcare) into buffer C (25 mM Tris (pH 8.5), 10 mM DTT, 200 mM NaCl).
In short, HsUBE1 was purified as follows. An Nterminal GST-Ub fusion pro tein was expressed and lysed in βmercaptoethanolfree lysis buffer and applied to Amintra glutathione resin (Expedeon). Upon washing, the resin was equilibrated with 50 mM Tris (pH 8.5) and 2 mM ATP. HsUBE1 βmercaptoethanolfree clari fied lysate was generated as above, supplemented with 10 mM ATP and 10 MgCl 2 and incubated with the GST-Ub fusionbound glutathione resin at room temper ature for 30 min. The resin was then washed with DTTfree high salt buffer sup plemented with 5 mM MgCl 2 . HsUBE1 was eluted in DTTcontaining buffer and proteincontaining fractions were applied to anionexchange and sizeexclusion chromatography as above. UBE2L3, UBE2D3 and GST-PhPINK1 were purified as described previously 33 . Generation of non-dischargeable E2-Ub complex. UBE2L3 (C86K) and ubiq uitin were stored in charging buffer (25mM CAPSO (pH 9.5), 20 mM MgCl 2 , 150 mM NaCl). UBE2L3 (C86K) (450 µM) was incubated with Ub (900 µM) and HsUBE1 (2.5 µM) in charging buffer supplemented with 10 mM ATP at 37 °C overnight. The resulting mixture was applied to sizeexclusion chromatography as above in buffer C. Fractions containing UBE2L3-Ub were pooled, concentrated and again applied to sizeexclusion chromatography to remove free UBE2L3. Ub-VS generation and parkin coupling. Ub(1-75)-MesNa was prepared as described previously 34 . HGlyVS hydrochloride was a kind gift from H. Ovaa and B.T. Xin (Leiden University). Ub-MesNa, stored in buffer D (20 mM HEPES, 50 mM sodium acetate (pH 6.5), 75 mM NaCl) at ~20 mg/ml, was used to dissolve ~50 mg HGlyVS hydrochloride together with ~30 mg of Nhydroxysuccinamide (Fluka), acting as a catalyst. The pH was raised to 8.5 by addition of ~60 µl of 4 M NaOH and reaction incubated at 37 °C. Reaction progress was monitored by LC-MS analysis. When the ratio of Ub(1-75)VS to hydrolysed Ub-MesNa product was ~1:1, with a minimum formation of the doubly coupled, Ub(1-75)-VS-VS species, the reaction was quenched by addition of 20 µl 12 M HCl (~30 min). The subsequent sample was diluted in 50 mM sodium acetate (pH 4.5) and applied to cationexchange chromatography on a 1ml MonoS column (GE Healthcare) with a 10-35% linear gradient between 50 mM sodium acetate (pH 4.5) containing 0 M and 1 M NaCl, respectively. The resulting fractions were analysed by LS-MS and Ub(1-75)-VS containing fractions were pooled and applied to sizeexclusion chromatography as above in buffer D.
For quantitative parkin-UbVS coupling, phosphoparkin was purified as above where 10 mM DTT in buffer C was replaced with 5 mM TCEP. Phosphoparkin and UbVS were mixed at a 1:3 molar ratio and incubated at room temperature. Reaction progress was monitored by LC-MS analysis and, upon completion, the reaction was quenched by addition of DTT (~30 min). The resulting sample was purified using sizeexclusion chromatography (buffer C). Mass-spectrometry analysis. LC-MS analysis was carried out on an Agilent 1200 Series chromatography system coupled to an Agilent 6130 Quadrupole mass spec trometer. Samples were eluted from a Phenomenex Jupiter column (5 ml, 300 Å, C4 column, 150 × 2.0 mm) using an acetonitrile gradient + 0.2% (v/v) formic acid. Protein was ionized using an ESI source (3 kV ionization voltage), and spectra were analysed in positive ion mode with a mass range between 400 and 2,000 m/z. Averaged spectra were deconvoluted using Promass (Novatia, LLC) and plotted using GraphPad Prism (version 7). Limited proteolysis. Tsparkin, phosphoTsparkin, phosphoTsparkin-phospho ubiquitin, and phosphoTsparkin-phosphoubiquitin charged with UbVS were purified as described above. A 1 mg/ml protein solution was mixed with 5 µg/ml solution of elastase from the ProtiAce Kit (Hampton research) and incubated for 1 h at room temperature. The reactions were quenched by addition of DTT and iodoacetamidecontaining LDS buffer and resolved on a 4-12% SDS NuPAGE gradient gels (Invitrogen) and stained with Instant Blue SafeStain (Expedeon). The quenched protein samples were rapidly thawed and subjected to proteolytic cleavage with pepsin followed by reversed phase HPLC separation. In brief, the protein was passed through an Enzymate BEH immobilized pepsin column, 2.1 × 30 mm, 5 µm (Waters, UK) at 200 µl/min for 2 min, the peptic peptides were trapped and desalted on a 2.1 × 5 mm C18 trap column (Acquity BEH C18 Van guard precolumn, 1.7 µm, Waters). Trapped peptides were subsequently eluted over 11 min using a 3-43% gradient of acetonitrile in 0.1% (v/v) formic acid at 40 µl/min. Peptides were separated on a reverse phase column (Acquity UPLC BEH C18 column 1.7 µm, 100 mm × 1 mm; Waters) and detected on a SYNAPT G2Si HDMS mass spectrometer (Waters) over an m/z of 300 to 2,000, with the standard electrospray ionization (ESI) source with lock mass calibration using [Glu1]fibrino peptide B (50 fmol/µl). The mass spectrometer was operated at a source temperature of 80 °C and a spray voltage of 2.6 kV. Spectra were collected in positive ion mode.
Hydrogen-deuterium exchange mass spectrometry (HDX-MS
Peptide identification was performed by MS e35 using an identical gradient of increasing acetonitrile in 0.1% (v/v) formic acid over 11 min. The resulting MS e data were analysed using Protein Lynx Global Server software (Waters, UK) with an MS tolerance of 5 ppm.
Mass analysis of the peptide centroids was performed using DynamX software (Waters). Only peptides with a score >6.4 were considered. The first round of analysis and identification was performed automatically by the DynamX software, however, all peptides (deuterated and nondeuterated) were manually verified at every time point for the correct charge state, presence of overlapping peptides, and correct retention time. Deuterium incorporation was not corrected for back exchange and represents relative, rather than absolute changes in deuterium levels. Changes in H/D amide exchange in any peptide may be due to a single amide or a number of amides within that peptide. Protein preparation for crystallization. TEVcleavable parkin was purified as described above. An anionexchange purified parkin sample (step 1) was incu bated with UbC3Br in a 1:4 molar ratio and GST-PhPINK1 in a 9:1 molar ratio in phosphorylation buffer (10 mM ATP, 10 mM MgCl 2 , 200 mM NaCl, 50 mM Tris (pH 8.5), 10 mM DTT) at a final parkin concentration of ~70 µM, yielding a phos phorylated, phosphoubiquitin conjugated, TEVcleavable parkin sample (step 2). GST-PhPINK1 was subsequently removed using Amintra glutathione resin (Expedeon). The sample was subjected to His 6 -TEV cleavage overnight at 4 °C (step 3). His 6 -TEV was removed using NiNTA agarose (Qiagen), sample diluted in buffer A and applied to anionexchange and sizeexclusion chromatography as described above.
To generate UbC3Br, Ub(1-75)-MesNa was prepared as described previ ously 34 . Ub-MesNa, stored in buffer D was incubated with 0.2 g/ml 3bromo propylamine hydrobromide (Fluka) dissolved in PBS (pH 4.8) at 2:1 molar ratio Letter reSeArCH with final Ub(1-75)-MesNa concentration of 445 µM. The coupling was carried out on ice for 30 min following addition of 50 µl 4 M NaOH to raise the pH to 10.5. The reaction was quenched by addition of 12 µl of 12 M HCl and sample buffer exchanged using a disposable PD10 desalting column (GE Healthcare) into buffer C. Crystallization. Initial crystals were found from crystallization experiments carried out at 18 °C in a 96well sitting drop vapour diffusion plates in the MRC format (Molecular Dimensions) by mixing 100 nl of 4 mg/ml protein solution with 100 nl reservoir solution. The crystallization condition of 12.5% (w/v) PEG 1000, 12.5% (w/v) PEG 3350, 12.5% (v/v) MPD, 0.03 M of each sodium nitrate, disodium hydrogen phosphate, ammonium sulfate, 0.1 M MOPS/ HEPESNa (pH 7.5) was found from the MORPHEUS screen (Molecular Dimensions). Seeds were obtained from a fine screen and streak seeding was car ried out in a hanging drop format from an 8 mg/ml protein solution. Larger crystals were obtained after 6 days in the original crystallization condition. Crystals were soaked in motherliquor supplemented with 10% (v/v) glycerol before vitrification in liquid nitrogen. Data collection, phasing and refinement. Diffraction data were collected at the Diamond Light Source, beamline I24 (0.9686 Å, 100 K), and processed using DIALS 36 . The crystal structure was determined by molecular replacement in Phaser 37 using the structure of the human parkin core (PDB 5N2W 6 ) truncated after the IBR, as well as a human parkin Ubl structure (PDB 5C1Z 19 ). The structure was built at 1.80 Å, in multiple rounds of model building in Coot 38 and refine ment in PHENIX 39 . Phenix ReadySetderived geometry restraints for the 3CN warhead were used, with external restraints defining the linkage points. Final Ramachandran statistics: 98.9% favoured, 1.1% allowed, and 0% outliers. Structural figures were generated using PyMol (http://www.pymol.org). Data collection and refinement statistics can be found in Extended Data Table 1 . Parkin activity assays. Ub-VS conjugation assays. Indicated parkin variants stored in either DTT or TCEPcontaining buffer were incubated with UbVS that was prepared as described above. The reactions were quenched at indicated time points by addition of DTT and iodoacetamidecontaining LDS buffer and resolved on a 4-12% SDS NuPAGE gradient gels (Invitrogen) and stained with Instant Blue SafeStain (Expedeon). Parkin assembly assays. Wildtype or R104A phosphoparkin (5 µM) were incu bated in ubiquitination buffer (30 mM HEPES (pH 7.5), 100 mM NaCl, 10 mM ATP, 10 mM MgCl 2 ) with HsUBE1 (0.2 µM), UBE2L3 (2 µM) and Ub (20 µM). The reactions were quenched at the indicated time points by addition of DTT and iodoacetamidecontaining LDS buffer and resolved on a 4-12% SDS NuPAGE gradient gels (Invitrogen) and transferred to a PVDF membrane (BioRad). Membranes were blocked in a 5% (w/v) milk solution in PBST (PBS + 0.1% (v/v) Tween20) for 30 min and incubated overnight at 4 °C with a ubiquitin recognizing antibody (Ubi1, NB300130, Novus Biologicals) in 5% (w/v) BSA in PBST and 0.1% (w/v) sodium azide. The membrane was then washed with PBST, incubated for 1 h at room temperature with antimouse IgGHRP (NXA931, GE Healthcare) in 5% (w/v) milk in PBST, washed in PBST and visualized using the Amersham Western Blotting Detection Reagent (GE Healthcare) and a ChemiDoc Touch Imaging System (BioRad). E2-Ub discharge assays. The UBE2D3-Ub conjugate was generated by incubat ing UBE2D3 (20 µM) with HsUBE1 (20 nM) and Ub (80 µM) in ubiquitination buffer supplemented with 5 µM CaCl 2 at 37 °C for 10 min. To remove remaining ATP, 0.5 U of Apyrase (NEB) was added and the reaction incubated at 30 °C for 30 min.
The discharge reaction was studied by addition of 1 µM wildtype or R104A phosphoparkin to a diluted charging reaction mixture (final UBE2D3 concen tration was 9 µM). The reactions were quenched at indicated time points by addition of DTTfree LDS buffer, while a final sample was collected at 11 min in DTTcontaining LDS buffer to assess the extent of isopeptidelinked UBE2D3-Ub species formation. Samples were resolved on 4-12% SDS NuPAGE gradient gels (Invitrogen) and stained with Instant Blue SafeStain (Expedeon). The gel band intensity was quantified in ImageJ by isolating the specific intensity of the UBE2D3~Ub thioester band as indicated, subtracting the background of the final reduced sample and normalized within each reaction. Thermal denaturation assays. Protein melting curves were recorded on a Corbett RG6000 real time PCR cycler (30 °C to 85 °C with 7 s per 0.5 °C). Samples con tained 4 µM parkin protein and 4×SYPRO orange in ubiquitination buffer + 5 mM TCEP. Melting curves were obtained as the maxima of dF/dT versus T plots. All data were recorded in triplicate. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. Data availability. Coordinates and structure factors have been deposited with the Protein Data Bank under accession code 6GLC. Uncropped versions of all gels are displayed in Supplementary Fig. 1 . All reagents and data are available upon reasonable request from the corresponding author. 6 ) as in a. Phosphoubiquitin binding leads to helix straightening, and IBR domain repositioning, which releases the Ubl domain for phosphorylation 5, 6 . In the shown structures of unphosphorylated parkin, the Ubl and REP (red) inhibit E2 binding, and the RING2-UPD interface is intact, with Cys431 being inaccessible. The Ubl-UPD linker was removed from crystallized constructs in a and c 6, 19 . (Fig. 1b-e) were plotted onto a stylized 'open domain' model of parkin, with identical colouring (blue, more protected from solvent exchange compared to previous state; red, less protected from solvent exchange compared to previous state). Grey regions correspond to peptides that were not covered or could not be analysed owing to modification. Schematic domain representations indicate an average change of the corresponding interfaces across all time points. White regions indicate no change. a, Parkin compared to parkin-phospho ubiquitin. b, Parkin-phosphoubiquitin compared to phosphoparkinphosphoubiquitin. c, Phosphoparkin-phosphoubiquitin compared to phosphoparkin-phosphoubiquitin in complex with an isopeptide UBE2L3-Ub thioester mimetic (see Methods). This experiment confirmed a previously reported binding site for the E2conjugated ubiquitin on the RBR 6,28 (8) . d, Phosphoparkin-phosphoubiquitin compared to UbVS reacted phosphoparkin-phosphoubiquitin. Reaction with UbVS leads to modification of the catalytic Cys431containingpeptide, generating nonidentical peptides precluding comparison by HDXMS. Low coverage of the RING2 domain can be explained by ubiquitin resistance to pepsin cleavage, leading to protection of the linked RING2 domain and subsequent peptide loss. To allow comparison, these peptides were also omitted from analysis of the UBE2L3-Ubbound sample. In c and d, the structure representation is deceiving because REP and RING2 are highly mobile and are no longer bound to the parkin core. Indeed, the high hydrogen-deuterium exchange in the REP sequence in active parkin ( Fig. 1d, e ; peptide (4) in Extended Data Fig. 2d) indicates an additional loss of secondary structure in this helical element when REP and RING2 are released. 
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Data exclusions
Describe any data exclusions. Data exclusion in crystallographic datasets (outlier reflection rejection) was carried out automatically as implemented in the program Xia2 using pre-established criteria. No biochemical data was excluded.
Replication
Describe whether the experimental findings were reliably reproduced.
All attempts at replications were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups. not applicable
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
not applicable
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
